Other Clinical Trial - Characterization of the Intrahepatic Inflammatory

Status Recruiting

Clinical Trial Summary

Non-alcoholic fatty liver disease (NAFLD) is a nosological entity that groups together non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Unlike NAFL, NASH is characterized by intrahepatic inflammation, and is solely at risk of progression to cirrhosis and hepatocellular carcinoma (HCC). It is currently estimated that NAFLD affects approximately 25% of the world's adult population, and its incidence is rising in all regions of the world. Nevertheless, of all patients with NAFLD, only ~25% have NASH. Identifying patients with NASH is therefore crucial, determining the need for follow-up to detect the onset of fibrosis and/or HCC, and eventual access to therapeutic trials. Furthermore, intrahepatic inflammation, the initial driver of NASH, appears to play an important role in the development of fibrosis and HCC, which can occur in the absence of cirrhosis in these patients. However, few studies have been carried out in humans to date, with data mainly coming from mouse models. An innovative technique, Fine-Needle Aspiration (FNA), enables to obtain cells from the liver compartment, including large numbers of immune cells. In participants with NAFLD and indication of liver biopsy, a FNA will also be performed. Forty patients will be included, with ~75% of NASH and ~25% of NAFL expected. The investigators will study the phenotypic and functional characteristics of human intrahepatic inflammatory cells obtained by the FNA with different innovative techniques (RNAseq, multiparameter immunophenotyping, single-cell secretome and phosphoproteome). Peripheral Blood Mononuclear Cells and circulating microRNAs, known to regulate immune responses, will also be analysed. The hypothesis of Profile-NASH is that intrahepatic inflammatory profiles differ between NASH and NAFL, and is associated with fibrosis progression and carcinogenesis. This pilot study, based on high-definition technologies, will provide precise new insights into the quality of intrahepatic inflammation and the mechanisms favoring the transition from NAFL to NASH and its progression. Precise analysis of the intrahepatic inflammatory microenvironment will enable the investigators to identify new players in the pathogenesis of NASH, and potential future therapeutic targets.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT06152250
Study type	Interventional
Source	Hospices Civils de Lyon
Contact	Yasmina CHOUIK, MD
Phone	04.72.07.12.02
Email	yasmina.chouik@chu-lyon.fr
Status	Recruiting
Phase	N/A
Start date	January 29, 2023
Completion date	January 29, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05255042` - Tissue Models for Liver Disease
Completed	`NCT04473482` - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Recruiting	`NCT03773887` - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease	N/A
Recruiting	`NCT00345930` - DILIN - Prospective Study
Completed	`NCT00148031` - Improving Hepatitis C Treatment in Injection Drug Users	Phase 4
Terminated	`NCT00031135` - Total Parenteral Nutrition-Associated Liver Disease	Phase 2
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00222664` - Qidong Hepatitis B Intervention Study	Phase 4
Recruiting	`NCT06195917` - Robotic-assisted Percutaneous Transhepatic Puncture	N/A
Recruiting	`NCT04551742` - Social & Contextual Impact on Children Undergoing Liver Transplantation
Completed	`NCT04782050` - Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Recruiting	`NCT05499585` - Treating Pediatric NAFLD With Nutrition	N/A
Terminated	`NCT03396705` - Liver Regeneration
Completed	`NCT04341012` - Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Recruiting	`NCT05733832` - A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis — Profil-NASH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms